All In Biotech

Drug Trial Radar · NCT07916259

The Study of Brave-LC LDN Treatment Trial

Brave-LC: A Phase 3 Randomized Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of a 16-week Course of Low-dose Naltrexone to Reduce Fatigue Severity in Persons Aged 6 Through 25 Years With Long COVID

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,300 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,300

Planned (sponsor's estimate)

Start

Nov 16, 2026

Primary completion

Dec 31, 2028

Study completion Jan 1, 2029

Sponsor

Sponsor type
NIH
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of a 16-week course of low-dose naltrexone (LDN) in approximately 1,300 participants aged 6 to 25 years with fatigue associated with Long COVID. Participants will be enrolled across three age cohorts (6-11, 12-17, and 18-25 years) and randomized 1:1 to receive LDN capsules or matching placebo capsules. LDN will be initiated at 1.5 mg daily and titrated weekly to a maximum tolerated dose of up to 4.5 mg daily. Randomization will be stratified by age cohort, and participants will also be randomized to a pharmacokinetic (PK) sampling window. Primary objective is to compare the change in fatigue severity from baseline to 16 weeks between participants aged 6 to 25 years with Long COVID randomized to a 16-week course of LDN or placebo.

Conditions

  • Post-acute COVID-19 Syndrome

Interventions

  • naltrexoneDrug

    Opioid receptor antagonist used to treat opioid and alcohol use disorders in adults. Formulated as naltrexone hydrochloride, a white, crystalline compound freely soluble in water.

  • PlaceboOther

    Matching placebo capsule that is visually identical to the active study product and is administered orally once daily according to the same dosing schedule and titration scheme for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS) total score.Time frame: Baseline to 16 weeks after randomization

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Children's of Alabama Child Health Research Unit (CHRU)

    Birmingham, Alabama

  • Exalt Clinical Research Inc.

    Chula Vista, California

  • Denver Health

    Denver, Colorado

  • University of Florida Health

    Gainesville, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts

  • Dartmouth Health

    Lebanon, New Hampshire

  • Rutgers Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • NYU Langone Hospital - Brooklyn

    Brooklyn, New York

  • Columbia University

    New York, New York

  • Baylor College of Medicine

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.